Celgene's psoriasis drug apremilast performs well in trial

03/4/2013 | Reuters

More psoriasis patients who took Celgene's experimental drug apremilast experienced improvements in symptoms compared with patients who took a placebo, a late-stage trial found. Celgene plans to submit the drug for FDA approval this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care